The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Login
EN
+7 (495) 482-4118
+7 (495) 482-0604
+8 800 101-59-87
  • (toll-free number for subscriptions)
    Mon-Fri from 10 a.m. to 6 p.m.

  • © 1998-2024
+7 (495) 482-43-29
EN
All journals
Journal
Year
Year
Search result: 0

Katargina L.A.

Helmholtz National Medical Research Center of Eye Diseases

Chesnokova N.B.

Helmholtz National Medical Research Center of Eye Diseases

Beznos O.V.

Helmholtz National Medical Research Center of Eye Diseases

Osipova N.A.

Helmholtz National Medical Research Center of Eye Diseases

Panova A.Yu.

Helmholtz National Medical Research Center of Eye Diseases

Pathogenetically oriented approach to prevention of retinopathy of prematurity (experimental study)

Authors:

Katargina L.A., Chesnokova N.B., Beznos O.V., Osipova N.A., Panova A.Yu.

More about the authors

Journal: Russian Annals of Ophthalmology. 2021;137(3): 26‑31

DOI: 10.17116/oftalma202113703126

Views: 883

Downloaded: 30

Download PDF (RU)
Contact the author
Table of contents

To cite this article:

Katargina LA, Chesnokova NB, Beznos OV, Osipova NA, Panova AYu. Pathogenetically oriented approach to prevention of retinopathy of prematurity (experimental study). Russian Annals of Ophthalmology. 2021;137(3):26‑31. (In Russ.)
https://doi.org/10.17116/oftalma202113703126

Подписка 2025 (Russian Annals of Ophthalmology)
 
МСФ на ЯМ
Close metadata

Intraperitoneal injections of exogenous melatonin during the development of the retinal vascular system in experimental rats has been shown in a number of experimental studies on the model of EROP to prevent the appearance of histological signs of the development of experimental retinopathy of prematurity (EROP), stabilize the blood-retinal barrier and have a pronounced antioxidant effect, but pathogenetic basis for these phenomena hasn’t been studied.

PURPOSE

To study the influence mechanism of melatonin and its analogues on the development of EROP at the preclinical stage of the pathological process to substantiate new approaches to prevention of ROP.

MATERIAL AND METHODS

The study included 42 Wistar rat pups (84 eyes) divided into 6 groups: control group, experimental group (rat pups with EROP), experimental groups who underwent injections of melatonin and its analogues K-148, AL-3, K-096. The pups were euthanized on day 7 (4—5 pups from each group at each study period), binocular enucleation was performed, and the content of hypoxia-induced factor1α (HIF-1α) and VEGF-A was determined in retinal samples.

RESULTS

The intraperitoneal injections of melatonin and its analogs led to a significant decrease in the level of HIF-1α and VEGF-A in the retina of the rat pups of the experimental group until the beginning of pathological vasoproliferation.

CONCLUSION

Melatonin and its analogues are able to prevent the development of EROP by reducing the level of angiogenic factors in the retina of rat pups at the stage of existing avascular zones, which allows for them to be considered as a new promising approach to preventing the development of ROP.

Keywords:

retinopathy of prematurity
preventive care
experimental study
melatonin
melatonin analogs

Authors:

Katargina L.A.

Helmholtz National Medical Research Center of Eye Diseases

Chesnokova N.B.

Helmholtz National Medical Research Center of Eye Diseases

Beznos O.V.

Helmholtz National Medical Research Center of Eye Diseases

Osipova N.A.

Helmholtz National Medical Research Center of Eye Diseases

Panova A.Yu.

Helmholtz National Medical Research Center of Eye Diseases

Received:

13.04.2020

Accepted:

01.06.2020

List of references:

  1. Katargina LA. Modern perspective on the problem of retinopathy of prematurity. Vestnik oftal’mologii. 2014;130(6):23-27. (In Russ.).
  2. Gilbert C, Bowman R, Malik A. The epidemiology of blindness in children: changing priorities. Commun Eye Health. 2017;30(100):74-77. 
  3. Saydasheva EI, Gorelik YuV, Buyanovskaya SV, Kovshov FV. Retinopathy of prematurity: the course and results of treatment in children with gestational age less than 27 weeks. Rossijskaja pediatricheskaja oftal’mologija. 2015;(2):28-32. (In Russ.).
  4. Neroev VV, Katargina LA, Kogoleva LV. The prevention of blindness and visual impairment in children with retinopathy of prematurity. Voprosy sovremennoj pediatrii. 2015;14(2):265-270. (In Russ.). https://doi.org/10.15690/vsp.v14i2.1296
  5. Yoon JM, Shin DH, Kim SJ, et al. Outcomes after laser versus combined laser and bevacizumab treatment for type 1 retinopathy of prematurity in zone 1. Retina. 2017;37(1):88-96.  https://doi.org/10.1097/IAE.0000000000001125
  6. Quinn GE, Dobson V, Hardy RJ, Tung B, Palmer EA, Good WV. Early Treatment for Retinopathy of Prematurity Cooperative Group. Visual field extent at 6 years of age in children who had high-risk prethreshold retinopathy of prematurity. Arch Ophthalmol. 2011;129(2):127-132.  https://doi.org/10.1001/archophthalmol.2010.360
  7. Quinn GE, Dobson V, Davitt BV, Wallace DK, Hardy RJ, Tung B, Lai D, Good WV. Early Treatment for Retinopathy of Prematurity Cooperative Group. Progression of myopia and high myopia in the early treatment for retinopathy of prematurity study: findings at 4 to 6 years of age. J AAPOS. 2013;17(2):124-128.  https://doi.org/10.1016/j.jaapos.2012.10.025
  8. Hwang CK, Hubbard GB, Hutchinson AK, Lambert SR. Outcomes after intravitreal bevacizumab versus laser photocoagulation for retinopathy of prematurity: a 5-year retrospective analysis. Ophthalmology. 2015;122(5):1008-1015. https://doi.org/10.1016/j.ophtha.2014.12.017
  9. Kang HG, Choi EY, Byeon SH, Kim SS, et al. Anti-vascular endothelial growth factor treatment of retinopathy of prematurity: efficacy, safety, and anatomical outcomes. Korean J Ophthalmol. 2018;32(6):451-458.  https://doi.org/10.3341/kjo.2018.0011
  10. Chan JJ, Lam CP, Kwok MK, Wong RL, Lee GK, Lau WW, Jam JC. Risk of recurrence of retinopathy of prematurity after initial intravitreal ranibizumab therapy. Sci Rep. 2016;6:27082. https://doi.org/10.1038/srep27082
  11. Hartnet ME. Advances in understanding and management of retinopathy of prematurity. Surv Ophthalmol. 2017;62(3):257-276.  https://doi.org/10.1016/j.survophthal.2016.12.004
  12. Hapsari D, Sitorus RS. Intravitreal Bevacizumab in Retinopathy of Prematurity: Inject or Not? Asia Pac J Ophthalmol (Phila). 2014;3(6):368-378.  https://doi.org/10.1097/APO.0000000000000039
  13. Moshfeghi DM. Systemic solutions in retinopathy of prematurity. Am J Ophthalmol. 2018;193:xiv-xviii. https://doi.org/10.1016/j.ajo.2018.05.013
  14. Katargina LA, Chesnokova NB, Beznos OV, Osipova NA. Melatonin as a new promising agent for the treatment and prevention of retinopathy of prematurity. Vestnik oftal’mologii. 2016;132(6):59-63. (In Russ.). https://doi.org/10.17116/oftalma2016132659-63
  15. Katargina LA, Khoroshilova-Maslova IP, Majbogin AM, Panova IG, Osipova NA. Pathomorphological features of the development of experimental retinopathy of prematurity. Mezhdunarodnyj zhurnal prikladnyh i fundamental’nyh issledovanij. 2017;3(2):190-194. (In Russ.).
  16. Chen J, Stahl A, Hellstrom A, Smith LE. Current update on retinopathy of prematurity: screening and treatment. Curr Opin Pediatr. 2011;23(2):173-178.  https://doi.org/10.1097/MOP.0b013e3283423f35
  17. Mutlu FM, Sarici SU. Treatment of retinopathy of prematurity: a review of conventional and promising new therapeutic options. Int J Ophthalmol. 2013;6(2):228-236.  https://doi.org/10.3980/j.issn.2222-3959.2013.02.23
  18. Xia Y, Choi HK, Lee K. Recent advances in hypoxia-inducible factor (HIF)-1 inhibitors. Eur J Med Chem. 2012;49:24-40.  https://doi.org/10.1016/j.ejmech.2012.01.033
  19. Pandi-Perumal SR, BaHammam AS, Brown GM, Spence DW, Bharti VK, Kaur C, Hardeland R, Cardinali DP. Melatonin antioxidative defense: therapeutical implications for aging and neurodegenerative processes. Neurotox Res. 2013;23(3):267-300.  https://doi.org/10.1007/s12640-012-9337-4
  20. Ozdemir G, Ergün Y, Bakariş S, Kılınç M, Durdu H, Ganiyusufoğlu E. Melatonin prevents retinal oxidative stress and vascular changes in diabetic rats. Eye (Lond). 2014;28(8):1020-1027. https://doi.org/10.1038/eye.2014.127
  21. Park SY, Jang WJ, Yi EY, Jang JY, Jung Y, Jeong JW, Kim YJ. Melatonin suppresses tumor angiogenesis by inhibiting HIF-1alpha stabilization under hypoxia. J Pineal Res. 2010;48(2):178-184. 
  22. Tosini G, Baba K, Hwang CK, Iuvone PM. Melatonin: an underappreciated player in retinal physiology and pathophysiology. Exp Eye Res. 2012;103:82-89.  https://doi.org/10.1016/j.exer.2012.08.009
  23. Blasiak J, Reiter RJ, Kaarniranta K. Melatonin in retinal physiology and pathology: the case of age-related macular degeneration. Oxid Med Cell Longev. 2016. https://doi.org/10.1155/2016/6819736

Close metadata

Contact the author
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

Contact us
If you have any questions, complaints or suggestions, please use this feedback form.
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.
Submit Application

You can become an author of one of our magazines, send a request and we will consider it in during the day.

Name
Phone
E-mail
Message
Login
Registration
E-mail
Password
Forgot Password?

Log in to the site using your account in one of the services

Password recovery
E-mail
Login
Register


We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.